MannKind Corporation (MNKD) Still Treading Water, So Why Are Investors Surfing?

Page 2 of 2

Suppose Al Mann is right, and Afrezza quickly becomes the top-selling insulin in the world. It would have to displace Sanofi’s Lantus, which generated more than $6 billion in revenue last year. If this happens, MannKind’s stock is a bargain at current prices.

Surf’s up
There are many who think the stock will fall. MannKind’s short percent of float stands at 30%.  The number of shares sold short has climbed around 85% since the beginning of the year. For now, though, more investors seem to think the surf’s up, and they continue to drive MannKind’s shares higher.

The first answers to what the future holds for MannKind Corporation (NASDAQ:MNKD) and its shareholders probably won’t be available until August when the Afrezza clinical results are announced. The next few months will likely feel like an endless summer for investors eagerly awaiting those findings.

In the meantime, MannKind really isn’t treading water, although that might appear to be the case from the outside. The company is frantically working to have those clinical results ready on schedule.

Investors definitely are hanging ten right now, though. Are they headed for a wipeout or a sustained ride on an epic wave? Leave your thoughts in the comments section below.

The article MannKind Still Treading Water, So Why Are Investors Surfing? originally appeared on and is written by Keith Speights.

Fool contributor Keith Speights has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned.

Copyright © 1995 – 2013 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Page 2 of 2